UK Pharmacies Test E-Cigarettes as Smoking Cessation Aid in Pilot Program

Nov.20.2024
UK Pharmacies Test E-Cigarettes as Smoking Cessation Aid in Pilot Program
A pilot program in Kent uses e-cigarettes for smoking cessation, aligning with the government's 2030 smoke-free target, as varenicline returns to NHS prescriptions after safety concerns.

The Community Pharmacy of England (CPE) announced that community pharmacies in Maidstone, Kent, are participating in a pilot program using e-cigarettes as a smoking cessation aid, according to The Pharmaceutical Journal on November 19.

 

Seven pharmacies are offering locally commissioned services, where smoking cessation advisors will provide patients with a voucher for a starter kit and up to a four-week supply of vape liquid. 

 

Patients can also access six other nicotine replacement products, though the service recommends vaping as a short-term aid for quitting smoking.

 

"The pilot is in response to the government's ambition for England to be smoke-free by 2030 and follows reflection by the Medway Public Health Team that, to achieve this, 50% of smokers will need to undertake a quit attempt every year," CPE said.

 

A Cochrane review published in September 2023 found that e-cigarettes, varenicline, and cytisine were the most effective aids for quitting smoking for six months or longer, with similar effectiveness among the three.

 

The review analyzed data from over 150,000 participants and showed that 10–19% of individuals quit smoking with e-cigarettes, 12–16% with varenicline, and 10–18% with cytisine.

 

"Community pharmacies already play a significant role in supporting people to stop smoking, but we believe more value could be created by the sector at a population health level as well as benefits to individuals, in line with the government's desire to achieve a smoke-free country and to reduce the use of vapes," the director of NHS services at the CPE, Alastair Buxton, said.

 

"Stopping smoking is not easy, but research shows that e-cigarettes are nearly twice as effective as nicotine replacement therapies, such as patches and gum, when used in a Stop Smoking Service setting," said Caroline Cerny, deputy chief executive at Action on Smoking and Health.

 

In November 2024, NHS England announced the reintroduction of varenicline for NHS patients, three years after its withdrawal due to high levels of N-nitroso-varenicline, a probable carcinogen. Previously a first-line smoking cessation treatment, varenicline was recalled by Pfizer in October 2021 over these safety concerns.

 

Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Azerbaijan's sweeping e-cigarette ban has raised concerns over enforcement errors and the emergence of illicit sales, while neighboring Armenia is tightening technical rules and preparing higher excise taxes. Georgia, meanwhile, has resisted calls for broader vape restrictions and introduced preferential taxes for some domestically produced cigarettes. The divergent approaches across the South Caucasus highlight a regional policy dilemma: how to curb nicotine use and protect public health without encouraging black markets or creating unintended economic consequences for businesses and consumers.
Nov.03